Creating a Path for Progressive CDI Programs: Learning Series 2022 - You are not alone, validating quality metrics - On Demand
Clinical documentation improvement (CDI) continues to advance beyond CC/MCC capture. Ensuring accurate Quality reporting and appropriately minimizing HAC and PSI reporting is crucial for a successful CDI team.
Target Audience
Nurses
CDI Specialists
Learning Objectives
1. Discuss the history and definitions of the HAC and PSI programs.
2. Recognize the different inclusion and exclusion criteria for common PSIs.
3. Assess the need for a CDI query, particularly to exclude the case from the PSI.
4. Demonstrate the best management system(s) for Quality reporting, including best-practice algorithms and teamwork functionality.
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System.docx | 79.2 KB |
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
FDA Off-Label Use
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
DISCLOSURE STATEMENTS:
The following planners, faculty, and others in control of educational content have no relevant financial relationships with ineligible companies.
Planning committee members
Rachel Mack, RN, MSN, BA, CCDS, CDIP, CCS, CRC
Consulting Director, CDI
Vizient, Inc.
Angela Hunt, RN, MBA, CCDS
Associate Principal, Advisory Solutions
Vizient Inc.
Linda Wiseman, RN, BSN, CCDS
Consulting Director, CDI
Vizient Inc.
Jim Tamburini, BS, RHIT, CCS, CCS-P, CDIP
Consulting Director, CDI
Vizient Inc.
Sheila Bowlds, RHIA, MBA, AHIMA Certified ICD-10 Trainer
Consulting Director, CDI
Vizient Inc.
Terry Golde, MBA, RN, CCDS
Consulting Director, CDI
Vizient Inc.
Erica Braun, MS, BSN, RN, CCDS
Consulting Director, CDI
Vizient Inc.
Marly Christenson, PhD, MS, RN, NP, CPHQ
Senior Director /Nurse Planner
Vizient Inc.
Speakers
Rachel Mack, RN, MSN, CCDS, CDIP, CCS, CRC
Consulting Director
Vizient, Inc.
Terry Golde, MBA, RN, CCDS
Senior Consulting Director
Vizient, Inc.
Connie Ryan, MBA, RN, CDIP
Consulting Director
Vizient, Inc.
Joint Accreditation Statement:
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statements:
NURSING
This activity is designated for 1.50 contact hours.
Vizient, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP12580, for 1.80 contact hours.
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).
Available Credit
- 1.50 ANCC
- 1.80 CBRN
- 1.50 General CE - Attendance